We chose scopoletin as a potential agent for its ability to inhibit the activation of nuclear factor-κB (NF-κB) against COPD-associated oxidative stress (Leema and Tamizhselvi, 2018). The gene discussed is NFKB1; the disease is chronic obstructive pulmonary disease.